Scarica l'app Stockscreener
705.44
0.32%
2.23
Dopo l'orario di chiusura:
703.20
-2.24
-0.32%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$703.21
Aprire:
$701.52
Volume 24 ore:
4.13M
Relative Volume:
0.96
Capitalizzazione di mercato:
$667.67B
Reddito:
$53.26B
Utile/perdita netta:
$13.80B
Rapporto P/E:
46.11
EPS:
15.3
Flusso di cassa netto:
$-50.20M
1 W Prestazione:
+6.81%
1M Prestazione:
-8.59%
6M Prestazione:
-19.20%
1 anno Prestazione:
-25.74%
Intervallo 1D:
$685.15
$705.80
Intervallo di 1 settimana:
$655.10
$714.27
Portata 52W:
$623.78
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
705.44 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.84 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
209.15 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
127.25 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.66 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly & Co Completes $6.71 Billion Notes Issuance - TipRanks
Eli Lilly Neuroscience Head Anne White to Retire After Three Decades with Company - geneonline.com
Lilly searching for new neuro chief as White set to retire - BioPharma Dive
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats - Benzinga
What's Going on With Eli Lilly Stock? - The Motley Fool
30-Year Veteran Who Led Lilly's Historic Alzheimer's Drug Launch: Anne White Announces Retirement - Stock Titan
Stock Option Traders Smell Blood in the Water After Eli Lilly’s (LLY) Q2 Fumble - TipRanks
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Benzinga
Eli Lilly (LLY) Sells Record $6.75 Billion of Corporate Bonds - TipRanks
How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo? - Seeking Alpha
Mixed options sentiment in Eli Lilly with shares up 1.67% - TipRanks
Eli Lilly & Co’s Orforglipron Faces Hold Rating Amid Concerns Over GI Side Effects in Clinical Trials - TipRanks
Positive Market Outlook for Eli Lilly’s Orforglipron Following ATTAIN-1 Trial Results - TipRanks
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks - Benzinga
Eli Lilly Considering Viking Therapeutics Acquisition?… - inkl
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year BondInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (NYSE:LLY): This US$700bn company is set to beat Novo Nordisk & Ozempic even with this month's hiccup - Stocks Down Under
Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide - TipRanks
Eli Lilly Files for $6.75 Billion Bond Offering - AInvest
Eli Lilly files for six-part notes offering of up to $6.75 billion - MarketScreener
Eli Lilly Taps High-Grade Bond Market With Rare 40-Year Paper - Bloomberg.com
Eli Lilly Launches $6.75 Billion Debt Offering - MarketScreener
Wall Street sees new obesity pills as priced near Wegovy and Zepbound - Reuters
Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data - Quiver Quantitative
Eli Lilly Taps High-Grade Market With Rare 40-Year Paper - Yahoo Finance
Lilly Stock Down 5% This Month: Should You Buy the Dip? - uk.finance.yahoo.com
Superluminal joins a $1.3B deal with series A backer Lilly - bioworld.com
Form 424B2 ELI LILLY & Co - StreetInsider
Daiwa Securities Downgrades Eli Lilly to Neutral From Outperform, Cuts Price Target to $700 From $940 - MarketScreener
The stock price pullback creates a good buying opportunity, and Eli Lilly and Co may soon join the "trillion-dollar club." - 富途牛牛
Superluminal Medicines, Eli Lilly forge USD 1.3 billion alliance to advance Small Molecule Therapeutics - Medical Dialogues
Eli Lilly and Company (LLY) Announces Results From LTE of Phase 3 TRAILBLAZER-ALZ 2 Study - uk.finance.yahoo.com
Eli Lilly: A Biotech Powerhouse Rewriting the Rules of Long-Term Growth - AInvest
Eli Lilly: Don't Bet Against This Biotech Powerhouse (NYSE:LLY) - Seeking Alpha
Eli Lilly's Q2 2025 Outperformance and Orforglipron Pipeline: A New Era for Obesity and Diabetes Therapies - AInvest
Eli Lilly (LLY) Raises Mounjaro Prices in UK, Stock Reacts Positively - MSN
Eli Lilly and Company (LLY) Releases Q2 2025 Results - uk.finance.yahoo.com
Eli Lilly’s Stock Soars Amid Promising Trials - TipRanks
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. - AOL.com
Novo Nordisk vs. Eli Lilly: Is the GLP-1 Correction Over, and Who's Better Positioned for Long-Term Leadership? - AInvest
Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly - TipRanks
Did Eli Lilly Stock Just Have Its Novo Nordisk Moment? - MSN
Eli Lilly Insider Buying: Lucas Montarce Purchases 715 Shares - AInvest
LLY CFO Makes Significant Investment in Eli Lilly & Co Stock - AInvest
Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why. - MSN
Eli Lilly & Co’s CFO Makes a Bold Move with New Stock Purchase! - TipRanks
Eli Lilly and Co Options Spot-On: On August 15th, 243.55K Contracts Were Traded, With 573.94K Open Interest - 富途牛牛
Eli Lilly & Co. hikes UK weight-loss drug’s price amid pressure from Trump - WISH-TV
Eli Lilly: Bet Against Insiders (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) CEO Buys $1 Million of Company Stock After Recent Crash - MSN
Eli Lilly and health-care stocks are week's big winners, 3 sectors in the red - CNBC
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lilly Eli Co Azioni (LLY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Alvarez Ralph | Director |
Aug 13 '25 |
Buy |
660.25 |
758 |
500,473 |
758 |
| Van Naarden Jacob | EVP & Pres., Lilly Oncology |
Aug 13 '25 |
Buy |
647.36 |
1,000 |
647,360 |
20,562 |
| Ricks David A | President, Chair, and CEO |
Aug 12 '25 |
Buy |
644.77 |
1,632 |
1,052,263 |
546,601 |
| Skovronsky Daniel | EVP, CSO & Pres. LRL & LLY Imm |
Aug 12 '25 |
Buy |
634.40 |
1,000 |
634,405 |
137,660 |
| Sulzberger Gabrielle | Director |
Aug 12 '25 |
Buy |
641.18 |
117 |
75,018 |
2,703 |
| Fyrwald J Erik | Director |
Aug 12 '25 |
Buy |
642.33 |
1,565 |
1,005,242 |
74,578 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Aug 11 '25 |
Sale |
627.01 |
1,250 |
783,762 |
26,260 |
| JACKSON JAMERE | Director |
Aug 08 '25 |
Buy |
639.56 |
200 |
127,913 |
9,402 |
| Seymour Melissa | EVP, Global Quality |
Aug 01 '25 |
Option Exercise |
0.00 |
952 |
0 |
952 |
| LILLY ENDOWMENT INC | 10% Owner |
Jul 24 '25 |
Sale |
805.07 |
280,000 |
225,419,259 |
95,736,978 |
0.58%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):